IHAM
FATE icon

Integral Health Asset Management’s Fate Therapeutics FATE Stock Holding History

Integral Health Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-700,000
Closed -$553K – 86
2025
Q1 		$553K Buy
700,000
+100,000
+17% +$123K 0.06% 81
2024
Q4 		$990K Sell
600,000
-375,000
-38% -$945K 0.08% 82
2024
Q3 		$3.41M Buy
975,000
+125,000
+15% +$486K 0.38% 54
2024
Q2 		$2.79M Buy
850,000
+650,000
+325% +$2.85M 0.26% 68
2024
Q1 		$1.47M Sell
200,000
-700,000
-78% -$4.33M 0.14% 80
2023
Q4 		$3.37M Buy
+900,000
New +$2.12M 0.46% 63
2022
Q1 		– Sell
-130,000
Closed -$7.61M – 79
2021
Q4 		$7.61M Buy
130,000
+35,000
+37% +$1.98M 2.1% 16
2021
Q3 		$5.63M Buy
95,000
+15,000
+19% +$1.18M 1.62% 22
2021
Q2 		$6.94M Buy
80,000
+40,000
+100% +$3.22M 1.91% 18
2021
Q1 		$3.3M Buy
+40,000
New +$3.83M 0.94% 41
2020
Q4 		– Sell
-85,000
Closed -$3.4M – 67
2020
Q3 		$3.4M Buy
85,000
+15,000
+21% +$524K 1.04% 34
2020
Q2 		$2.4M Sell
70,000
-25,000
-26% -$745K 0.72% 52
2020
Q1 		$2.11M Buy
+95,000
New +$2.4M 0.93% 39

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Integral Health Asset Management's FATE Position: Q2 2025 in Review

Integral Health Asset Management sold out of Fate Therapeutics (FATE) in Q2 2025, closing a stake of 700,000 shares — an estimated $553K sold.

Integral Health Asset Management first reported a position in FATE in Q1 2020 and held it in 13 quarters. The position peaked at $7.61M in Q4 2021. 139 funds tracked by Wall St. Rank hold FATE as of Q2 2025.

  • Integral Health Asset Management reported no remaining Fate Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Integral Health Asset Management sold 700,000 Fate Therapeutics shares in Q2 2025, an estimated $553K.
  • Integral Health Asset Management first reported a position in Fate Therapeutics in Q1 2020 and held it in 13 quarters.
  • Integral Health Asset Management's Fate Therapeutics position peaked at $7.61M in Q4 2021.
  • 139 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2025.

Based on Integral Health Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.